Elahere (mirvetuximab soravtansine-gynx) / AbbVie 
Welcome,         Profile    Billing    Logout  
 0 Diseases   17 Trials   17 Trials   934 News 


1234567891011»
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Journal:  HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract. (Pubmed Central) -  May 7, 2026   
    FOLR1 met current MIRV treatment criteria in one case, while ten others showed expression ranging from 5% to 70%. Although most tumors did not meet current biomarker thresholds for Trastuzumab or MIRV monotherapy, detectable expression supports exploring anti-HER2 T-Dxd and MIRV combination treatments in selected MA/MLA cases.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer
    Journal, Real-world evidence:  Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers? (Pubmed Central) -  Apr 30, 2026   
    Real-world ADC outcomes were consistent with pivotal trials, with no independent survival differences by subgroup after adjustment. These findings support continued investigation of clinical and structural factors influencing outcomes.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR?) (S100bc) -  Apr 21, 2026 - Abstract #ASCO2026ASCO_689;    
    P2
    Funded by Eli Lilly and Company Clinical Trial Registration Number: NCT07213804 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by ImmunoGen/AbbVie Clinical Trial Registration Number: NCT04274426 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Trial completion date, Trial primary completion date, Platinum sensitive:  An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (clinicaltrials.gov) -  Apr 14, 2026   
    P2,  N=53, Recruiting, 
    Multimodal imaging combined with functional and refractive assessment provides sensitive markers of corneal epithelial toxicity and supports integrated ophthalmologic monitoring to preserve visual function and maintain oncologic treatment continuity. Trial completion date: Oct 2028 --> Jan 2031 | Trial primary completion date: Jan 2028 --> Jan 2029
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    Elahere in Real World: USA (102AB) -  Apr 11, 2026 - Abstract #SGO2026SGO_1092;    
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    Journal, Tumor mutational burden, IO biomarker:  Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary. (Pubmed Central) -  Apr 9, 2026   
    FOLR1 expression in the two cases was weak and below currently used clinical cutoffs for mirvetuximab soravtansine eligibility...Only a subset of anaplastic carcinomas of the ovary express targetable tumor antigens at low levels, suggesting that these may have limited benefit from antibody-drug conjugates. Likewise, due to mismatch repair proficiency and low tumor mutational burden, immunotherapy is unlikely to be effective in this rare disease.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    Real-world Evaluation of Ocular Toxicities Associated with Mirvetuximab Soravtansine in the Treatment of Recurrent Ovarian Cancer (Exhibit Hall I2) -  Mar 28, 2026 - Abstract #HOPA2026HOPA_277;    
    No external funding was used. Results Results pending Conclusion/Discussion Results Pending Definitions: FR?-Positive: Tumors are considered FR?-positive if ?75% of viable tumor cells demonstrate membranous staining with at least 2+ intensity on immunohistochemistry (IHC) testing, consistent with the diagnostic criteria used to select patients for mirvetuximab soravtansine therapy.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer
    Review, Journal:  Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions. (Pubmed Central) -  Mar 25, 2026   
    Furthermore, the inherent complexities of these drugs and their mechanisms of action underscore the need for further research into the relevance of biomarkers, methods of therapy resistance, and the potential for re-utilization of payloads and targets later in the disease course. This review focuses on the mechanisms of action of ADCs, their developmental trajectory, successes in gynecologic cancers, emerging areas of investigation, the prospective landscape, and current challenges in the field.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    A Novel FOLR1 and TRAIL-R2 targeting bispecific antibody to treat ovarian cancer (Section 20) -  Mar 17, 2026 - Abstract #AACR2026AACR_7782;    
    This study reveals a previously unappreciated mechanism in antibody therapeutics: the use of a tumor-enriched anchor (FOLR1) to optimize death receptor clustering and activation, enabling a quantum leap in apoptotic signaling and therapeutic index for ovarian cancer. The TRAILBody platform thus offers a foundation for next-generation immuno-oncology agents and revives hope for the clinical translation of death receptor agonism, particularly in solid tumors marked by immune exclusion and therapeutic resistance.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Drug repurposing in Nectin-4-positive epithelial ovarian cancer (Section 13) -  Mar 17, 2026 - Abstract #AACR2026AACR_7668;    
    This study demonstrates the therapeutic potential of Nectin-4-targeted agents in preclinical models of Nectin-4-positive EOC, supporting their advancement toward clinical translation. Additionally, the findings suggest that repurposing Nectin-4-guided combination therapy could expand and enhance treatment options for EOC.
  • ||||||||||  BCG047 / Biocytogen
    BCG047, a novel heavy chain antibody-drug conjugate targeting FOLR1, demonstrates outstanding preclinical antitumor efficacy (Section 53) -  Mar 17, 2026 - Abstract #AACR2026AACR_6762;    
    These data suggest that BCG047 is a promising therapeutic strategy targeting FOLR1, with the potential to expand the patient population benefiting from this treatment, particularly in low FOLR1 expression settings. To enhance pharmacokinetics and improve efficacy, modifications to BCG047 aimed at achieving a prolonged half-life are currently underway for further preclinical development.
  • ||||||||||  sofetabart mipitecan (LY4170156) / Eli Lilly
    LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits enhanced antitumor activity in combination with standard-of-care therapies in preclinical ovarian cancer models (Section 15) -  Mar 17, 2026 - Abstract #AACR2026AACR_4823;    
    P1, P3
    levels or prior mirvetuximab soravtansine-gynx treatment, and without grade ?3 drug-related ocular, neuropathy, or alopecia events.3 The Phase 3 study (NCT07213804) evaluates LY4170156 as monotherapy in patients with PROC and in combination with bevacizumab in patients with platinum-sensitive ovarian cancer (PSOC)...In vivo efficacy studies showed that LY4170156 combined with cisplatin with or without bevacizumab, bevacizumab, doxorubicin, or carboplatin plus paclitaxel resulted in superior and more durable antitumor responses compared to SoC alone...Furthermore, LY4170156 plus olaparib demonstrated enhanced antitumor activity in DNA repair-deficient models...2023; 389(23):2162-2174 3Ray-Coquard et al. Presented at ESMO 2025.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    A novel pH dependent T cell engager platform for next generation cancer therapeutics (Section 10) -  Mar 17, 2026 - Abstract #AACR2026AACR_4613;    
    Low expression of FolR1 in normal tissues is restricted to the luminal surface of lung, kidney, intestine, etc. ELAHERE, the approved FolR1 ADC demonstrated great clinical efficacy to FolR1high patients but is ineffective to FolR1low patients...These findings suggest that WuXi Biologics' FolR1 TCE offers significant therapeutic potential as a next-generation TCE with minimal on-target-off-tumor cytotoxicity and enhanced therapeutic window. The pH dependent design provided an innovative strategy to offer safer and more effective therapeutic overcome for solid cancer patients.
  • ||||||||||  ZW191 / Zymeworks
    ZW191 - a differentiated FR?-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs (Section 13) -  Mar 17, 2026 - Abstract #AACR2026AACR_4476;    
    P1
    by virtue of its novel and highly effective FR?-targeted antibody and its novel ZD06519 TOPO1i payload...Here, we demonstrate ZW191's strong antitumor activity in a xenograft model of ovarian cancer when dosed in combination with each of the platinum-based drug carboplatin, the microtubule inhibitor paclitaxel, and the anti-angiogenic antibody bevacizumab...A clinical landscape analysis demonstrates that moderate potency ADC payloads facilitate higher dosing levels in the clinic. Together with encouraging early clinical data that highlight ZW191's single agent activity and differentiated safety profile, these data reinforce its potential to achieve meaningful efficacy gains through combination with other agents.
  • ||||||||||  DXC011 / Hangzhou DAC Biotech
    DXC011, a novel dual-payload antibody-drug conjugate targeting folate receptor alpha (Section 38) -  Mar 17, 2026 - Abstract #AACR2026AACR_4357;    
    Collectively, these findings indicate that DXC011 offers an improved therapeutic index and may enable expanded indication coverage. DXC011 represents a novel FR?-targeted dual-payload ADC that achieves potent and broad antitumor activity with enhanced tolerability, supporting its advancement toward clinical development.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Kadcyla (ado-trastuzumab emtansine) / Roche
    Quantitative analysis of microtubule lattice damage in NF1-deficient HER2-positive breast cancer under mitotic and pharmacological stress (Section 25) -  Mar 17, 2026 - Abstract #AACR2026AACR_3748;    
    EB1 shaft localization and mitotic defects (chromosome missegregation, aneuploidy) were rescued by NF1 re-expression.By establishing a quantitative framework to measure EB1 redistribution at single MT resolution, our study provides a previously unavailable strategy to monitor intra-lattice damage in cancer cells. These findings establish for the first time a direct causative link between unrepaired MT damage and chromosomal instability, providing a new model to understand maytansinoid mechanism of action.
  • ||||||||||  ifinatamab deruxtecan (DS-7300) / Daiichi Sankyo, Merck (MSD), Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Emrelis (telisotuzumab vedotin-tllv) / AbbVie
    Ex vivo micro-tumor testing platform to guide patient stratification for clinical development of ADCs (Room 28 - Upper Level - Convention Center) -  Mar 17, 2026 - Abstract #AACR2026AACR_2574;    
    A reduced correlation was observed for MIRV and carboplatin (R = 0.59), that acts by crosslinking DNA...The platform is future-ready, offering multimodal capabilities including tumor microenvironment (TME) characterization, target protein profiling capturing patient heterogeneity, and assessment of bystander and synergistic responses. The next step is to correlate the ex vivo sensitivity to actual clinical outcome.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Avastin (bevacizumab) / Roche, Rubraca (rucaparib) / Pharma& Schweiz
    Review, Journal, BRCA Biomarker, PARP Biomarker:  Targeting VEGF, PARP, and FR? Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. (Pubmed Central) -  Mar 14, 2026   
    Collectively, VEGF-, PARP-, and FR?-targeted therapies have enabled more rational treatment sequencing, informed combination strategies, and personalized clinical decision-making in ovarian cancer. Ongoing efforts to define optimal sequencing, overcome acquired resistance, and refine predictive biomarkers are expected to further enhance the durability and breadth of benefit from targeted therapies and advance precision oncology in gynecologic malignancies.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Avastin (bevacizumab) / Roche
    Journal:  Ovarian Cancer Therapy. (Pubmed Central) -  Mar 7, 2026   
    N Engl J Med 381: 2416-2428. doi:10.1056/NEJMoa1911361].
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    From Treatment to Trauma: A Case of Mirvetuximab-Soravtansine Induced Interstitial Lung Disease (Area B, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P227) -  Mar 3, 2026 - Abstract #ATS2026ATS_2007;    
    Further investigation is warranted to determine the exact mechanism of toxicity and establishing treatment recommendations. Current treatment suggestions for severe toxicity include permanent cessation of the drug and high dose intravenous steroids.
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    Grade 4 Pneumonitis Due to Mirvetuximab Soravtansine-gynx (MIRV) in a Patient With Ovarian Cancer (Area B, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P225) -  Mar 3, 2026 - Abstract #ATS2026ATS_2005;    
    Although this patient responded to corticosteroids, other potential therapies include tocilizumab, infliximab, mycophenolate, IVIG, and cyclophosphamide. Prompt recognition and early corticosteroid treatment remain critical for improving outcomes.